ARIEL4 Trial Confirms PFS Benefit of Rucaparib in BRCA+ Relapsed Ovarian Cancer

As reported by Cancer Network, new results from a phase 3 clinical trial testing the drug rucaparib (Rubraca), which has already been approved by the U.S. Food and Drug Administration, show that it prolongs progression-free survival in some patients with advanced ovarian cancer.